PDS Biotechnology Corp
PDSB · XNASCIK 1472091fmd_1RJ34HG0K0ZCBB12KWP36NHZMFManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Jun 30, 2026, 51 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 25 | 34 | 1 | 6 | 8 | 11 | 29 | 28 | 23 | 19 |
| Total operating expenses | 40 | 52 | 4 | 21 | 15 | 21 | 42 | 43 | 36 | 32 |
| Operating income | (40) | (52) | (4) | (21) | (15) | (21) | (42) | (43) | (36) | (32) |
| Interest expense | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 4 | 5 | 5 |
| Interest and investment income | – | – | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 1 |
| Other non-operating income (expense) | – | – | (0) | – | – | – | – | – | – | – |
| Income before taxes | (41) | (53) | (4) | (7) | (15) | (21) | (42) | (44) | (38) | (36) |
| Income tax expense | (2) | (3) | 0 | (0) | 0 | (5) | (1) | (1) | (1) | (1) |
| Net income from continuing operations | (39) | (51) | (4) | (7) | (15) | (17) | (41) | (43) | (38) | (34) |
| Net income | (39) | (51) | (4) | (7) | (15) | (17) | (41) | (43) | (38) | (34) |
| Net income to common shareholders | (39) | (51) | – | – | – | – | – | – | – | – |